NovoCure (NVCR) Surges 10.7%: Is This an Indication of Further Gains?Zacks Investment Research • 10/16/24
Novocure Shoots Skyward, Reversing Setbacks, After FDA Approves Lung Cancer TreatmentInvestors Business Daily • 10/15/24
FDA Approves Novocure's Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung CancerBusiness Wire • 10/15/24
Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) TherapyBusiness Wire • 09/09/24
Wall Street Analysts Think NovoCure (NVCR) Could Surge 35.96%: Read This Before Placing a BetZacks Investment Research • 08/16/24
Novocure Highlights TTFields Therapy in Treatment of Non-Small Cell Lung Cancer at 2024 World Conference on Lung CancerBusiness Wire • 08/14/24
Wall Street Analysts Believe NovoCure (NVCR) Could Rally 26.39%: Here's is How to TradeZacks Investment Research • 07/30/24
METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free SurvivalBusiness Wire • 06/03/24
TIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in GermanyBusiness Wire • 05/23/24
Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from PharmakonBusiness Wire • 05/02/24
NovoCure (NVCR) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 04/25/24
Results of Novocure's METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024Business Wire • 04/24/24
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024Business Wire • 04/05/24